/
Other
Phase 1
53
Pipeline Programs↗
55
Active Trials↗
176
Companies Involved↗
Phase 1 is a moderately active landscape with 53 programs across 176 companies. The most active players are Luye Pharma Group Ltd., AbbVie, Sichuan Honghe Biotechnology Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 144
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
44 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.
Analysis
Trial Status
465
clinical trials
Completed352 · 76%
Recruiting26 · 6%
Terminated25 · 5%
Unknown status19 · 4%
Not yet recruiting15 · 3%
Active, not recruiting14 · 3%
Other14 · 3%
Clinical Trials
Trial Activity
465 trials
Page 1 of 31
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)